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Probabilistic sensitivity analyses were also performed using
Monte Carlo simulations.
Results: Based on our Markov model, AZT-3TC-efavirenz
had the lowest cost of treatment (USD $12.09 per day)
and the highest rate of success (69%). It was the primary
cost-effective HAART for HIV/AIDS in Colombia. AZT-3TC-
efavirenz dominated all other HAART treatments. Results
were generally robust within ranges tested.
Conclusion: In Colombia, antiretroviral therapy will lead
to major survival beneﬁts and is cost-effective by World
Health Organization criteria. The availability of second-line
regimens will further increase survival, but their cost-
effectiveness depends on their relative cost compared with
ﬁrst-line regimens.
doi:10.1016/j.ijid.2010.02.2027
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Prevalence of metabolic abnormalities and metabolic syn-
drome in a cohort of hispanic patients on HAART
E. Bissio1,∗, G. Lopardo2
1 FUNCEI, Buenos Aires, Argentina
2 Corunna, Argentina
Background: Metabolic abnormalities are a well known
side-effect of HAART. However, some studies show similar
prevalences of metabolic syndrome in patients on HAART
and the general population. According to different studies,
prevalence of metabolic syndrome in the general popula-
tion ranges from 23.7% to 24.6% using the ATP III deﬁnition.
The aim of this study was to determine the prevalence
of metabolic abnormalities and metabolic syndrome in a
cohort of hispanic patients on HAART attending an ID Clinic
in Buenos Aires, Argentina.
Methods: Retrospective cross-sectional study. The
records from the patients were reviewed to determine
prevalence of the metabolic syndrome (as deﬁned by the
NCEP ATP III Update), and the prevalence of metabolic
abnormalities.
Results: The cohort was composed of 78 hispanic
patients on stable HAART for at least 6 months (mean age:
40.89± 8.55 years [range: 22—64]; 9% were women). Mean
CD4: 583± 282 cells/mm3; median VL: 50 (IQR: 50—50).
The general prevalence of the metabolic syndrome was
24.7% (95% CI 15.6-36.8). The prevalence among patients on
a protease inhibitor(PI)-based regimen (n = 15) was 26.7%,
versus 24.2% among those without PI (p =NS). In this last
group, those on efavirenz (n = 43) had a prevalence of 26.2%
compared to 14.3% those on nevirapine (p < 0.05). The age-
speciﬁc prevalence in the 30-39 years group was 22.2%, and
32.1% in the 40-49 years group. The prevalence of hyper-
trigliceridemia was 47.4%, but differed according to therapy
group (PI, EFV or NVP; mean values (mg/dL): 240± 322.76;
165± 109 and 150± 80.4; respectively), and increased with
age group (20-29: 33%, 30-39: 45.7%, 40-49: 50%). General
prevalence of low HDLwas 37.3% (women: 42%, men: 38.2%);
there was no difference between patients with or without
PI; but in this last group, prevalence among those on EFV was
42.5% vs 21.41% in those on nevirapine (p < 0.05). Hyperten-
sion prevalence was 39.5%.
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Conclusion: In this cohort, prevalence of the metabolic
yndrome was similar to the prevalence in the gen-
ral population. However, patients on protease inhibitors
nd efavirenz had a higher prevalence than those on
evirapine (and the general population). Drug-induced
ypertrigliceridemia seems to be one of the major drivers
eading to the emergence of the metabolic syndrome among
hese patients.
oi:10.1016/j.ijid.2010.02.2028
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edication errors in patients receiving antiretroviral
herapy at an urban hospital
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University of Miami, 33125, FL, USA
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Background: Combination Antiretroviral therapy (ART)
as decreased morbidity and mortality for persons with
uman immunodeﬁciency virus (HIV) infection. These
omplex regimens involve three or more agents, and
here are many potential errors. The errors in prescrib-
ng ART may lead to adverse/toxic effects, treatment
ailure, and drug resistance. We evaluated medication
rrors occurring among patients receiving ART at the
iami VAMC to identify potential interventions to decrease
rrors.
Methods: This was a retrospective study utilizing a med-
cal chart review to evaluate medication prescribing errors
ccurring among patients who had received ART during Jan-
ary 1 through December 31, 2007 at the Miami VAMC.
sing the DHHS guidelines for HIV therapy as a source, we
creened for the following prescribing errors: inappropri-
te dosing, use of inappropriate regimens/combinations,
se of other medications and ART when contraindicated,
ailure to adjust for renal insufﬁciency, and insufﬁcient mon-
toring. In addition, we evaluated the frequency of errors
ccurring during admission in comparison to the out patient
linic.
Results: The medical charts of 833 patients of whom
14 (62%) were receiving ART were reviewed. A total of 24
igniﬁcant prescribing errors involving antiretrovirals were
etected. Themost common errors involved failure to adjust
or renal insufﬁciency (54%) followed by use of contraindi-
ated combinations with potential for drug interactions
46%). Overall, 17% of the errors occurred while the patient
as admitted to the hospital. Although 75% (3) of the errors
n the inpatient group were due to renal dosing as opposed to
5.5% (10) in the outpatient group; this was not statistically
igniﬁcant. Similarly, there was no statistical difference
egarding contraindicated combination medications among
oth groups.
Conclusion: In this Patient population, the most fre-
uent errors involved failure to adjust ART in the face
f renal insufﬁciency and the co-administration of con-
raindicated medications with ART. These errors can be
voided by automated alerts in the computerized medical
ecord used at this facility and emphasizing to physicians
he importance of adjusting dosage or changing the ART
o account for renal insufﬁciency. System-based interven-
